Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALOTHANE vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Induction and maintenance of general anesthesia,Sedation in intensive care (off-label),Status asthmaticus (off-label, due to bronchodilation)
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Halothane is metabolized in the liver primarily by cytochrome P450 2E1 (CYP2E1) to trifluoroacetic acid and bromide ion; reductive metabolism also produces chloride ions and free radicals.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
Approximately 20-30% bound to plasma proteins, primarily albumin and lipoproteins.
50-60%, primarily to albumin and α1-acid glycoprotein.
Volume of distribution at steady state (Vdss) approximately 2-5 L/kg; large Vd indicates extensive tissue distribution, especially to adipose tissue, brain, and muscle.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
100% bioavailable via inhalation (only route of administration). Oral bioavailability not applicable.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
No specific dose adjustment required for renal impairment; use with caution due to potential nephrotoxicity from fluoride ions.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
Child-Pugh Class A: no adjustment; Child-Pugh Class B and C: avoid use; contraindicated in patients with hepatic impairment or history of halothane-induced hepatotoxicity.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
Induction: 0.5-2% in oxygen or oxygen-nitrous oxide mixture, gradually increased; Maintenance: 0.3-1.5% as needed. Use lowest effective dose.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
Reduce dose by 25-50% due to increased sensitivity and reduced clearance; monitor hemodynamics closely.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
Halothane can cause hepatic necrosis, which may be fatal. Fatalities have occurred in patients with previous halothane exposure. Avoid repeat exposure within 3-6 months.
No FDA black box warning.
Hepatotoxicity (halothane hepatitis), malignant hyperthermia, cardiac arrhythmias (sensitizes myocardium to catecholamines), respiratory depression, hypotension, increased intracranial pressure.
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to halothane, known or suspected susceptibility to malignant hyperthermia, history of unexplained jaundice or fever after halothane, hepatic dysfunction following previous halothane exposure, pregnancy (relative, especially first trimester).
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
No specific food interactions. However, fasting is required before anesthesia to reduce aspiration risk. Alcohol should be avoided for at least 24 hours post-anesthesia due to additive CNS depression.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated with a potential increased risk of congenital malformations based on limited epidemiological data. Second and third trimester use may cause fetal depression and uterine atony; prolonged exposure can lead to neonatal respiratory depression. Avoid use during pregnancy unless clearly needed.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Halothane is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4. Due to low oral bioavailability, risks to the nursing infant are minimal. However, caution is advised as effects on the infant have not been fully studied. Consider pumping and discarding milk for 24-48 hours after anesthesia to minimize exposure.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No specific dose adjustment is recommended, but pregnancy alters pharmacokinetics: increased volume of distribution and decreased protein binding may require higher initial doses to achieve desired anesthetic depth. However, due to increased sensitivity to myocardial depression and uterine relaxation, use the minimum effective dose. Reduce concentration as needed to maintain uterine perfusion and avoid fetal hypoxia.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Halothane is a volatile halogenated hydrocarbon anesthetic. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias; avoid epinephrine use. Associated with halothane hepatitis (immune-mediated hepatotoxicity), especially with multiple exposures. Malignant hyperthermia trigger; have dantrolene ready. Use with caution in patients with increased intracranial pressure as it can elevate ICP. Use with low fresh gas flows to minimize pollution and cost.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
This medication will make you unconscious for surgery. You will not feel pain or remember the procedure.,You must fast before anesthesia; do not eat or drink for at least 6-8 hours before surgery.,Tell your anesthesiologist about any liver problems or previous reactions to anesthesia.,Notify your doctor if you have a personal or family history of malignant hyperthermia.,Avoid alcohol for at least 24 hours after anesthesia.,Do not drive or operate machinery for 24 hours after receiving halothane.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
"Efonidipine, a dihydropyridine calcium channel blocker, inhibits L-type and T-type calcium channels, leading to vasodilation and reduced myocardial contractility. Halothane, a volatile inhalational anesthetic, depresses myocardial function and sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Concurrent use can result in additive negative inotropic effects and profound hypotension, potentially leading to cardiovascular collapse."
"Halothane, a volatile anesthetic, can inhibit the cytochrome P450 enzyme CYP2B6, which is primarily responsible for the metabolism of bupropion, an antidepressant and smoking cessation aid. This inhibition leads to decreased clearance of bupropion, resulting in elevated plasma concentrations that increase the risk of dose-dependent adverse effects such as seizures, anxiety, and insomnia. Clinically, patients may exhibit heightened neuropsychiatric toxicity and reduced seizure threshold, particularly during and after halothane anesthesia."
"Halothane, a volatile halogenated anesthetic, inhibits cytochrome P450 (CYP) isoenzymes, particularly CYP2C19, which is crucial for the hepatic bioactivation of clopidogrel to its active metabolite. Concomitant administration can lead to reduced plasma concentrations of the active thiol metabolite of clopidogrel, diminishing its antiplatelet effect and increasing the risk of thrombotic events such as stent thrombosis or myocardial infarction in patients with coronary artery disease. This interaction is especially significant in patients undergoing surgery where halothane is used for anesthesia while clopidogrel is indicated for recent acute coronary syndrome or percutaneous coronary intervention."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALOTHANE vs ARALEN HYDROCHLORIDE, answered by our medical review team.
HALOTHANE is a General Anesthetic that works by Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALOTHANE and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALOTHANE is: Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALOTHANE and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALOTHANE is classified as Category C. Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated w. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.